Madrigal Pharmaceuticals stock gains 2.93% as Madrigal Pharmaceuticals UK announces BSG Liverpool event

Traders Union
All News
Companies
Madrigal Pharmaceuticals jumps 2.93% today

Highlights

MDGL faces short- and medium-term selling pressure, trading just below key moving averages with long-term support emerging near recent lows.
Momentum indicators are mixed, with bearish MACD, weak trend signals, and mostly neutral to oversold oscillators pointing to prevailing caution.
MDGL is likely to remain rangebound between $475.10 and $502.56 in the coming week, with downside risk favored unless key resistance breaks.

Seller pressure holds as price hovers near key moving averages

MDGL is trading at $494.88, placing it just below the MA-20 at $496.99 and under the MA-50 at $511.91, while sitting slightly above the MA-200 at $492.04. This positioning suggests short- and medium-term pressure from sellers remains, but with possible long-term support emerging. The current price is just under the Ichimoku Kijun level at $496.22, which now acts as immediate resistance. For near-term levels, support is seen at the MA-200 ($492.04). Key support sits at the MA-100 ($488.84). Near-term resistance is defined by the Ichimoku Kijun ($496.22), with key resistance coming from the MA-50 ($511.91).

Recovery momentum splits with lingering bearish signals and neutral trend

Momentum signals are mixed: MACD on D1 points to a bearish setup, while ADX remains neutral and reflects a lack of strong trend conviction. RSI and CCI are both in sell territory, showing the market is drifting lower but not strongly oversold. Stoch RSI and BBP indicate mostly neutral to oversold conditions, and BBP's negative value highlights a modest dominance of sellers intraday. In today's session, MDGL has gained 2.93%, with price action clustered at the top of the weekly range, fueling a sense of momentum. Over the past week, MDGL is up $14.11 or 2.96% from the previous weekly close at $480.77. Weekly volatility stands at 5.35%. The price is now at the very top of the weekly range, suggesting a strong recovery from the weekly low and possible near-term exhaustion. The combination of indicators and price action shows a split between short-term upward moves and broader hesitancy.

Downside bias prevails as rangebound trade limits breakout risks

For the coming week, the expected price range is $475.10 to $502.56, which remains well within 20% of the current price and situates MDGL in the upper portion of its annual band between the 52-week low of $275.00 and 52-week high of $615.00. The probability of an upward move is very low (less than 20%), as only the weekly MA-50 presents a buy signal, while RSI W1, ADX W1, and MACD W1 are largely neutral or bearish. The opposite move—downward—is much more likely. In the baseline scenario, MDGL is likely to remain rangebound near the $475 to $502 area. In a bullish scenario, a break above $502.56 could open the way for a test of the MA-50 resistance zone near $511.91. In a bearish scenario, a drop below $475.10 could see the price probing the MA-200 and MA-100 support near $492 and $488, introducing short-term volatility and possible further downside.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Madrigal Pharmaceuticals was exhibiting bullish momentum, supported by positive technical signals and strong recent performance. As current market conditions evolve, traders should now monitor for shifts in sentiment or volatility that could present actionable opportunities in the near term.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.